Research Articles

My Top 3 Fabulous Pharma Stocks

Chuck Carnevale - Monday, June 08, 2015

Introduction

I am a fervent believer that investment decisions should be made based on the relative merits of each individual investment under consideration.  However, my anecdotal observations and experience suggests that many investors do not embrace that approach.  This is especially true regarding investment decisions on common stocks.  Instead of focusing on the opportunities and valuations available from select individual businesses, many investors are obsessed, and I allege blinded by generalized views or beliefs about the overall market and/or the economy.

For example, in a recent article found here I postulated about reasons why carefully selected growth stocks might benefit retired investors under certain circumstances.  In the article I presented a few examples of high-quality fast-growing businesses that I considered fairly valued based on their earnings growth rates.  Unfortunately, and as I expected might happen, a comment made in the article rejected my carefully selected growth stock research candidates based on what I believe are misguided views about the market in general.  The comment is included in its entirety as follows:

“I like growth stocks but not when the market is at all time highs and way overpriced as it is now. Just for example, the Russell 2000 is at a P/E of 40 and P/B of 4 - hardly compelling valuations.

Many growth stocks should be sold short here and that is what I am doing. When the market tanks (soon) I will close out my shorts and go long on some of the growth stocks I like. 

Making a decision on buying a stock without looking at its relative valuation and that of the market is a dangerous proposition and one I am not interested in.”

To clarify my position, I offer the following elaboration and critique regarding why I found this comment concerning.  First of all, the reference that the P/E ratio and price-to-book ratio of the Russell 2000 were at all-time high valuations was not relevant to the valuations of the individual research candidates I presented.  Each of the companies I presented was offered because I believed their valuations were in alignment with their past, present, and most importantly, their future earnings potential.  The valuation of the Russell 2000 was therefore irrelevant.

The second paragraph also offered a generalized view of growth stocks and suggested that they should be sold short.  But again, I don’t believe this statement relates specifically to the candidates I offered in the article.  Then the bold prediction was made that the market would tank soon, which of course, is impossible to accurately forecast.  However, the comment also indicated that this could be timed to perfection by closing out shorts and then investing in growth stocks that were favored.  Again, I contend that this is impossible to time or predict.

Finally, the comment suggested that buying a stock without looking at its relative valuation and that of the market was a dangerous proposition.  Of course, I vigorously agree that investors should evaluate the valuation of the company, but only based on its specific fundamental merits, regardless of the valuation of the overall market.  I elaborated on my belief that it’s a market of stocks and not a stock market in a recent article found here

The Pharma Sector Powerful Demographic Forces Support Growth Potential

Therefore, I was motivated to offer this follow-up article on growth stocks for retirement portfolios by offering three attractive looking growth stock research candidates in the Pharma sector.  Thanks to the demographic forces of an aging population, I contend that the Pharma sector offers enormous growth potential that is independent of the general economy or the stock market.

As I indicated in my previous article on the appropriateness of growth stocks in retirement portfolios, they are not necessarily a good fit for every retired investor.  However, for those investors at or near retirement that are interested in adding some growth, I offer the following three Pharma growth stock opportunities that I am personally researching.  Most importantly, my initial review indicates that each of these candidates are reasonably valued based on their respective future growth opportunities.

Three Fabulous Pharma Growth Stocks

Two of the following three Pharma growth stocks were originally previewed in my previous article.  In this article I have added a third Pharma research candidate in what follows is my reasoning as to why I consider these attractive growth opportunities based on my preliminary research.  Perhaps readers of this article that have more information or familiarity with any of these companies will help the rest of us by sharing their knowledge.

To get a free more detailed perspective on these three Pharma stocks, follow this direct link to a video on my site mistervaluation.com and watch and listen to me analyze these companies out loud via the FAST Graphs fundamentals analyzer software tool.

Actavis plc (ACT)

Actavis, my first research candidate, is well-positioned to serve the growing pharmaceutical needs of our aging population.  The company offers both branded and generic pharmaceuticals worldwide. 

Short business description courtesy of S&P Capital IQ:

“Actavis plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic, branded generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution.

The North American Brands segment provides patented and off-patent trademarked pharmaceutical products primarily under the Dalvance, Bystolic, Canasa, Carafate, Daliresp, Fetzima, Linzess, Namenda, Namenda XR, Saphris, Teflaro, Viibryd, Actonel, Asacol HD, Atelvia, Delzicol, Doryx, Estrace Cream, Enablex, Lo Loestrin Fe, and Minastrin 24 Fe brands.

The North American Generics and International segment develops, manufactures, and sells generic, branded generic, and OTC pharmaceutical products.

The Anda Distribution segment distributes generic and brand pharmaceutical products primarily to independent pharmacies, pharmacy chains and buying groups, and physician’s offices.

The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, gastroenterology, urology, and dermatology areas.

The company sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers, and distributors, including national retail drug and food store chains, hospitals, clinics, mail order retailers, government agencies, and managed healthcare providers.

It has a collaboration agreements with Amgen, Inc. to develop and commercialize biosimilar versions of Herceptin, Avastin, Rituxan/Mab Thera, and Erbitux; Ironwood Pharmaceuticals to develop and commercialize Linzessfor the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; Sanofi-Aventis U.S. LLC; and Trevena for the development of TRV027. Actavis plc was founded in 1983 and is headquartered in Parsippany, New Jersey.”

Both demographics and acquisitions have stimulated accelerating earnings growth since 2011.  Nevertheless, Actavis trades at P/E ratio that is less than its historical earnings growth achievement.  However, the normal P/E ratio has moderately expanded as a result of extraordinary growth in 2013 and 2014. 

Importantly, Actavis has also generated cash flow growth that is aligned with its historical earnings growth.  Consequently, the company has ample resources to continue funding research and development and its reasonable 36% debt-to-capital ratio is well covered.

Growth in earnings and cash flow since 2010 has resulted in significant total returns for Actavis shareholders.  Returns have significantly out-performed the general market, which is extraordinary when you consider that this timeframe has produced one of the best returns for the S&P 500 in recent history.  The stock market has nothing to do with the results that Actavis achieved. 

Looking to the near to intermediate time future, leading analysts continue to expect earnings growth in excess of 20% per annum for this fiscal year and next.  The company’s current P/E ratio is in alignment with this near-term forecast growth.  Consequently, the company offers double-digit return potential over the next couple of years.

The following analyst scorecard summarizes analysts’ accuracy when making earnings forecasts one year and two year forward.  This provides additional confidence that Actavis might meet earnings forecasts for the next two years.

Analysts also provide 3-5 year earnings estimates.  The consensus of 9 analysts expects long-term (3-5 years) earnings growth to average slightly less than 15% per annum.  This lower long-term forecast offers a potential negative to this company’s ability to generate double-digit returns longer term.  Although this is still a high earnings growth rate, the company’s current P/E ratio would indicate higher-than-optimum current valuation over the longer term.

The following slides provide additional insight into the growth opportunities for Actavis.  For a more comprehensive review of the full presentation, follow this link.

Valeant Pharmaceuticals International (VRX)

Valeant Pharmaceuticals is also well-positioned to serve the growing pharmaceutical needs of our aging population.  However, this candidate offers additional diversification due to the specific markets that it serves.

Short business description courtesy of S&P Capital IQ:

“Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide.

The company offers Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer. It also provides Zovirax, an antiviral for recurrent herpes labialis and initial genital herpes; Syprine to treat patients with Wilson's disease; Elidel to treat atopic dermatitis; Prolensa for inflammation and pain following cataract surgery; Duromine, a weight loss drug; and Lotemax gel for post-operative inflammation and pain.

In addition, the company offers PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; ReNu Multiplus to lubricate and rewet soft contact lenses; Biotrue for healthy contact lens wear; Ocuvite, a lutein eye vitamin and mineral supplement; cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; AntiGrippin for acute respiratory and respiratory viral diseases, and influenza; and Bedoyecta, a vitamin B complex product.

Further, it provides SofLens daily disposable contact lenses; PureVision, a contact lens; various ophthalmic surgical products; Biotrue ONEday lens; medical device systems for aesthetic applications; and Bausch + Lomb Ultra, a contact lens.

Additionally, the company offers Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Cardizem CD to treat hypertension and angina; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.”

Valeant Pharmaceuticals represents a second example of accelerating earnings growth since 2010.  Even though the company has experienced P/E ratio expansion thus far in 2015, I believe the company is still soundly-valued based on earnings potential. 

The biggest negative I find with this candidate is its high debt-to-capital ratio of 79%.  However, accelerating cash flow generation supports the company’s ability to service the debt, and as we will see with the follow-up slide presentation, the company is committed to reducing its debt moving forward. 

Once again we see an example of extraordinary historical performance as a result of strong operating results.  The total return potential from investing in growth stocks is powerful and significant, and not related to general stock market returns.

On a short-to-intermediate-term basis, Valeant may be moderately overvalued.  However, thanks to the power of compounding, the company still offers the potential for total returns exceeding 20% per annum out to 2017.

Once again the analyst scorecard summary indicates a high success rate for analyst forecasts made one year and two years prior to actuals.  Consequently, this provides some evidence that current forecasts may be reasonable and accurate.

In contrast to what we saw with Actavis, long-term (3-5 year) analyst forecasts are strong at over 20% per annum on average.  Consequently, from a long-term total return perspective, Valeant may be the strongest choice.  However, that higher future return is somewhat less appealing based on the company’s current debt load.

The following slides summarize the opportunity in front of Valeant.  Note the discussions on cash flows and the balance sheet on the last slide.  For a more comprehensive review of the full presentation, follow this link



Celgene Corporation (CELG)

Although my final candidate, Celgene, has the lowest historical growth since 2010 of the three, it has also had the most consistent double-digit growth over a longer period of time.  Consequently, although recent performance has been moderately lower than my first two examples, this is my favorite candidate of the three.

Short business description courtesy of S&P Capital IQ:

“Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally.

It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML).

The company’s products also include THALOMID for the patients with multiple myeloma and for the treatment of cutaneous manifestations of erythema nodosum leprosum; OTEZLA for psoriatic arthritis, psoriasis, and ankylosing spondylitis; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products.

 Its clinical stage products comprise oral anti-inflammatory agents targeting PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; cellular therapies, such as PDA-001 and PDA-002 for Crohn’s and peripheral arterial diseases; CC-486 to treat MDS, AML, and solid tumors; Sotatercept and luspatercept for the treatment of anemia; and CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers.

The company has collaborative agreements with Novartis Pharma AG; Acceleron Pharma; Agios Pharmaceuticals, Inc.; Epizyme Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; MorphoSys AG; Acetylon Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; and NantBioScience, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.”

As previously mentioned, I favor the consistent growth that this company has historically achieved.  But more importantly, and as we shall soon see, expectations are for future growth to continue at or above its historical achievements.

Celgene’s debt-to-capital ratio is reasonable at 46% and supported by strong and accelerating cash flow growth. 

Although historical performance since 2010 has been lower than my first two candidates, it is still extraordinary when compared to the average company. 

Since we cannot invest in the past, only the future, the future growth expectations of Celgene are the primary reason I favor it over the other two candidates.  Importantly, it appears that Celgene is soundly-valued based on earnings growth estimates exceeding 25% over the next two years.


The one year forward and two year forward analyst scorecard for Celgene is also encouraging.   The company has met or exceeded analyst estimates over 70% of the time.

 

Regarding longer-term 3-5 year growth, Celgene is expected to grow faster than the previous candidates.  Given this company’s consistent historical record, I believe the potential for total annualized returns exceeding 20% are well-defined.


The following slides illustrate the important and large opportunities that Celgene serves.  For a more comprehensive review of the full presentation, follow this link.

 

Summary and Conclusions

The three Pharma companies presented in this article offer intriguing potential for above-average future long-term earnings growth.  Importantly, based on that earnings growth potential, each of them appear soundly valued at current levels.  However and perhaps most importantly, their growth potential is, for the most part, independent of the overall economy.  Each of these companies possess unique characteristics supported by the powerful demographic trend of an aging population. 

Consequently, I believe it’s worth putting concerns about the market or economy aside, and focusing instead on the opportunities that each of these big Pharma growth stocks offer.  Finally, I remind the reader that I have not personally completed my research and due diligence.  Therefore, I suggest that further comprehensive research and due diligence should be conducted.  On the other hand, the long-term total return potential of each of these candidates seems worthy of that effort.

Disclosure:  No position at the time of writing.

Disclaimer: The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients. Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted. The information in this document is believed to be accurate, but under no circumstances should a person act upon the information contained within. We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation.

 


Testimonials


“I appreciate your work, Chuck. As a subscriber to FAST Graphs™, I use the tool to decide on whether to purchase additional shares of what I currently hold or to add a new holding. Your articles help me make full use of the tool and give other readers valuable information, if they take the time to learn. One of the biggest enhancements that I use is the FFO data added for MLPs and REITs.”


“When FAST Graphs™ were unavailable because of Hurricane Sandy, I realized how much I need them in order to make investment decisions.

(Wish I could be) Long FAST Graphs!!!”


“One more vote for the value of FAST Graphs™; just started a subscription to Chuck's great service (premium), and am having a ball analyzing so many stocks quickly.”


“I feel very ill-equipped to make investment decisions without Fast Graphs. :-)”


“Yesterday, I signed up for your F.A.S.T. Graphs™. It's a really amazing, valuable tool for checking over/undervaluation of stocks. Wish I had it years and years ago!!”


“Love the F.A.S.T. Graphs™: One glance and you know a whole lot.”


“About Chuck's F.A.S.T. Graphs™: They are invaluable to me in making decisions about the stocks I own (in addition to what you are saying about doing other research) and the ones I hope to own in the future.”


"Chuck -- Your proprietary F.A.S.T. Graphs™ are a VERY impressive tool!"


“If there were an Investor Hall of Fame for people who have helped others with their investing, and sharing valuable information, you and your F.A.S.T. Graphs™ would get one of my selections.”


“I love Chuck's F.A.S.T. Graphs™! Well worth the price of admission for what he gives you.”


"Chuck - Thank you for your well thought out articles. I tend to be a visual type of person so I really appreciate the F.A.S.T. Graphs™ approach."


"Great article, as always! I always look forward to your articles, and am especially eagerly awaiting your next in this series. I find the F.A.S.T. Graphs™ extremely helpful."


“Your F.A.S.T. Graphs™ put all of this in a single artful picture and the accompanying spreadsheets hammer home the point.”


“I use the F.A.S.T. Graphs™ method to evaluate all of my ideas. I recommend it for individual investors, since it helps them focus on data and get past the many emotional arguments.”


“I recently subscribed to the F.A.S.T. Graphs™, and these articles are helping me learn how to better use them. They really do give you a good quick look at the valuations picture. A much needed tool!”


“I also always appreciate the clear-cut information provided through your F.A.S.T. Graphs™ and articles.”


“Thanks, Chuck, for your F.A.S.T. Graphs™. Each of these graphs is worth 1,000 words in describing a company's growth, consistency and valuation. Thanks for sharing your graphs.”


“Thanks, Chuck. Love the F.A.S.T. Graphs™! It makes investing so much more clear.”


“Chuck's F.A.S.T. Graphs™: They are invaluable to me in making decisions about the stocks I own (in addition to what you are saying about doing other research) and the ones I hope to own in the future.”


”I am amazed at the usefulness of your F.A.S.T. Graphs™ and I plan on using them for a long time to come.”


“Chuck's F.A.S.T. Graphs™ will give you a tool to find those well chosen stocks...”


“Thanks for the F.A.S.T. Graphs™, Chuck. They are the best tool I've used.”


Recent Posts


Tags

high-yield IBN T BCE AMT NSR ENSG DividendIncome CTG FRAN blue chip TWGP GWW WVR JWN GEOS value investing SHPG ACN MNTX BOFI CSL JCOM NVS Dividend Ideas CAT AMAG SWFT MUR mid-sized investing for income,growth and income stocks RDS.A ARLP VMI BA DRC MAIN BG HD IBM ACOM O Telecommunications cashflow intrinsic value,stocks,earnings,fundamentals,stock research tool,due diligence BF.B WY GILD GD BCR Fundamentals SIG WGL dividend growth REITs GNTX FBHS PPL WWW IDA TUP RJF stock research ITW, UTX Materials CanadianBanks WFM SILVER market currents BKH Champions earnings growth ITC CBU MNK ConsumerDiscretionary GLT XRX DRI HBI NOG TEVA fast-growing ITW TOT intrinsicvalue KO,CLX,CELG,JCP,GT,MSI,PEP,ED BLK JWML.Y JCI food service regional banks CAM ZUMZ CXRX DR retirement GOOGL BRS NC GPCM WIN FB Valuation CCK HCBK V MCY RAI CELG CR THC TE DIS GT KALU CRLI CTRX DividendChampions AFL,CVX,ED,JNJ,MCD,PG,SWK,T,WMT,TGT,ABM,AFL,BEN,BMS,CB,CBSH,CTBI EMR XOM PFE AMG ACM BNS above-average THRM suvivorship basis LMT CVS D ALB NSC FAF AFL AVP CFR ABM CHD LTM AMBN ETR JAZZ AVD long-term investing STMP JOY UL ANTM RRD 3NSRGY RKT dividend growth investing SYT FTR ARRS Stock Research Analysis BAC capital appreciation dividend paying stocks SHW KCAP CHS ICLR DGX DVA QCOR PRXL AM FLO POM SoundValuation GME SBR OHI UTHR GOLD value trap KO F WBA VRTU CACI XEL AZZ ACI HE InformationTech AEG ASNA PNR EBAY diversified machinery KMT MNST RIMM portfolio HSC PB WAG NPM AIG MCHP value-oriented SNI investing for income MAT TEG: WEC: AAP EAT LOW cash flow act EWBC ROST free cash flow CAH dividend COP OSIS LEN KSS ORI SLW DECK UEPS biotech DHR OUTR MRK PRAA LQDT EMR, MMM fair valuation AMGN PII HGT fundamental stock research tool ATW TWX Consumer discretionary LZB VRX AOS DOM ACE RSG,RTN HSY BMO NTES PNW OHI,EPR,WPG,JLL BAX URI HighQuality MHS PAG SJM ABT MTW ACR NEE best-of-breed TIF ETP CTL OZRK P Utilities GIS FOMC HCA BIDU MPW NOC FC LKQ ADM FinancialSector AAN INFY long-term CKSW FTI,HTZ ACQ DNB MKC HIBB ANDE stock analysis ZBRA AAPL DAN SEIC dividend income CRI CE COO MYL US Economy hyper growth stocks BNS. BOKF PNM TIS WLP IR MGEE BMRC MHP CLF ABBV dividendpaying SBUX value WEC WMT BLL GMCR PEP EE K DFS CL DTE Buffett MSA investing TSM RBC CVX ESRX RS GOOG dividend-paying BIIB TGH BOBE dividends machinery SCG ORCL CLX,EMR SIVB GPI due diligence NKE SO ALTE HP CTSH MCD M ECHO Bond,TGT,UTX Contenders INWK WHR market TICC TAC GE AEP FF INGR HOG AFG ECL FLIC MGA AFAM VAL RCII PKG SWKS CTCM SCL dividend paying LLL stock research tool GAS long-term growth SCHW ED:SCG UNH HPQ KR SPY utility stocks BANF OKE IPAR X TNC TROW Market Outlook OGE TGT Utilities Sector DKS FRED DRIP PNRA THFF CATY interest rates WRLD ADP MELI Macro view CNC EXLS marketvaluation VTR HII JKHY EMC MA MSCC AMP BCOR BMS fastgraphs JRN LXU dividend-growth EK Challengers POT stockResearchTool CGY EPHC beta ETN DPS LO MSFT SNH SUBX FCFS AA RSO DD THO LINE QCOM DLR HNZ macro UNM CIO NA market timing CBRL DDS BBBY long PCLN WSM PBI PSX CHE RMD short ideas investing for total return AKRX HCN TGI FAST DividendAristocrats INTC CMI sell BEN CNSL AET HON ONE KMB KFT HSNI BAP CTAS CLR WST BHP biotechnology LLY DGAS consumer SAM DMRC ROSE BPL BDX WMT,ROST,GIS,GE,JNJ,KO OKS EXC MIDD GES VCO DORM BMTC PCL MMM POWR COST VZ PM MNR NFLX SHR SBRA APEI SYNA MDT MATW VVC SU CBI AGLP SYK PCP AMCX WU suvivorship Share Buybacks JNJ LH UHS FDX Dividend Champions TSCO FairlyValued MTZ SFG CLX CTBI COL technology dividendGrowth NROM FL COH treasury HCP highqualityR PEG FairValuation RY BBY VFC HCI DLPH R ADT AIRM CAPE BWLD KMP investment long ideas mid-cap HRL DOW EV cyclical AZO BH economy PPG JPM FUL SYY GPS RRC InterestRates healthcare earnings UNP SXL SLGN DTEGY CPN HAS ESI Yield CPB NLY CASY TMP ENDP PFG CERN TU NSRGY FAST Graphs RTN BRLI PortfolioDesign APD dividends,earnings growth CACC growth Aristocrats INT TEF MDP WASH CINF SAVE BigFive,Canadian STE FISV DELL EnergySector blue-chip C intrinsic value AMZN CSX ED DE LL SPLS SON CVX,SWK,MCD,TGT,PG,WMT,JNJ,MDT,AFT,T,ED DTV long-term returns REXX BEAV Industrial DollarCostAverging MCK AB DOV JSFT SHOO WFC growth stocks stock CM MO Aristocrat TRV ULTA MAN BWP HRS FOSL true worth fair value SNCR GPC BHB Overvalued PG OXY CB PDFS AXP FDO PRGO TXT BR banks ODFL ABC TNGO SWK RSG UN SRCE total return APH GrowthOriented ATHM AFSI AGN MGRC POR OII utility CSCO IR,

Archive

Testimonials


“I appreciate your work, Chuck. As a subscriber to FAST Graphs™, I use the tool to decide on whether to purchase additional shares of what I currently hold or to add a new holding. Your articles help me make full use of the tool and give other readers valuable information, if they take the time to learn. One of the biggest enhancements that I use is the FFO data added for MLPs and REITs.”


“When FAST Graphs™ were unavailable because of Hurricane Sandy, I realized how much I need them in order to make investment decisions.

(Wish I could be) Long FAST Graphs!!!”


“One more vote for the value of FAST Graphs™; just started a subscription to Chuck's great service (premium), and am having a ball analyzing so many stocks quickly.”


“I feel very ill-equipped to make investment decisions without Fast Graphs. :-)”


“Yesterday, I signed up for your F.A.S.T. Graphs™. It's a really amazing, valuable tool for checking over/undervaluation of stocks. Wish I had it years and years ago!!”


“Love the F.A.S.T. Graphs™: One glance and you know a whole lot.”


“About Chuck's F.A.S.T. Graphs™: They are invaluable to me in making decisions about the stocks I own (in addition to what you are saying about doing other research) and the ones I hope to own in the future.”


"Chuck -- Your proprietary F.A.S.T. Graphs™ are a VERY impressive tool!"


“If there were an Investor Hall of Fame for people who have helped others with their investing, and sharing valuable information, you and your F.A.S.T. Graphs™ would get one of my selections.”


“I love Chuck's F.A.S.T. Graphs™! Well worth the price of admission for what he gives you.”


"Chuck - Thank you for your well thought out articles. I tend to be a visual type of person so I really appreciate the F.A.S.T. Graphs™ approach."


"Great article, as always! I always look forward to your articles, and am especially eagerly awaiting your next in this series. I find the F.A.S.T. Graphs™ extremely helpful."


“Your F.A.S.T. Graphs™ put all of this in a single artful picture and the accompanying spreadsheets hammer home the point.”


“I use the F.A.S.T. Graphs™ method to evaluate all of my ideas. I recommend it for individual investors, since it helps them focus on data and get past the many emotional arguments.”


“I recently subscribed to the F.A.S.T. Graphs™, and these articles are helping me learn how to better use them. They really do give you a good quick look at the valuations picture. A much needed tool!”


“I also always appreciate the clear-cut information provided through your F.A.S.T. Graphs™ and articles.”


“Thanks, Chuck, for your F.A.S.T. Graphs™. Each of these graphs is worth 1,000 words in describing a company's growth, consistency and valuation. Thanks for sharing your graphs.”


“Thanks, Chuck. Love the F.A.S.T. Graphs™! It makes investing so much more clear.”


“Chuck's F.A.S.T. Graphs™: They are invaluable to me in making decisions about the stocks I own (in addition to what you are saying about doing other research) and the ones I hope to own in the future.”


”I am amazed at the usefulness of your F.A.S.T. Graphs™ and I plan on using them for a long time to come.”


“Chuck's F.A.S.T. Graphs™ will give you a tool to find those well chosen stocks...”


“Thanks for the F.A.S.T. Graphs™, Chuck. They are the best tool I've used.”